- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea
Journal: New Developments in Topical Acne Therapy. (Pubmed Central) - Mar 15, 2022
Trifarotene, a novel fourth-generation retinoid, has demonstrated improved tolerability compared with existing topical retinoids...The late-phase clinical trials pipeline consists of agents with bactericidal and anti-sebum mechanisms. Although it is evident that acne treatments continue to evolve, it is important to recognize the need for further comparative studies among new and existing agents to define optimal treatment algorithms that address not only safety and efficacy but also cost-effective care.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Trifarotene - The latest retinoid. (Pubmed Central) - Jan 19, 2022
Not yet recruiting --> Recruiting No abstract available
- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: 50 Years of Topical Retinoids for Acne: Evolution of Treatment. (Pubmed Central) - Aug 25, 2021
Efforts to improve tolerability have utilized novel delivery systems and/or novel agents. This qualitative literature review summarizes the evolution of the four topical single-agent retinoids available for the treatment of acne in the US today and their various formulations, presenting the rationale behind their development and data from key studies.
- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: Trifarotene for acne. (Pubmed Central) - Aug 24, 2021
This qualitative literature review summarizes the evolution of the four topical single-agent retinoids available for the treatment of acne in the US today and their various formulations, presenting the rationale behind their development and data from key studies. No abstract available
- |||||||||| Aklief (trifarotene) / Galderma
Clinical, Review, Journal: Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris. (Pubmed Central) - Aug 5, 2021
We focus on efficacy, safety, and tolerability data and highlight quality of life outcomes and patient-reported satisfaction. Future clinical trials and the clinical applicability of this novel medication in the treatment of acne are also discussed.
- |||||||||| Aklief (trifarotene) / Galderma
Review, Journal: Updated Treatment for Acne: Targeted Therapy Based on Pathogenesis. (Pubmed Central) - Jun 12, 2021
In particular, specific emphasis on aggressive treatment in the acute inflammatory phase to reduce the likelihood of scarring and other clinical sequelae, such as pigmentary changes would be highly desirable. Treatment for established acne-induced sequelae should also be considered.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Identification and verification immune-related regulatory network in acne. (Pubmed Central) - Apr 21, 2021
Finally, we found that isotretinoin and trifarotene (CD5789) treatment repressed the expression of immune genes but not the expression of the kinases and TFs, indicating that kinases and TFs may be novel therapeutic target for acne. In conclusion, 3 kinases and 2 TFs were identified and validated as key regulators in the immune-related regulatory networks in acne, providing a more comprehensive understanding and novel therapeutic targets of acne.
- |||||||||| Aklief (trifarotene) / Galderma
[VIRTUAL] Trifarotene Transcriptomics Analysis and Acne-Related Gene Expression () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_182;
Interestingly, those genes were downregulated as compared to the papule signature suggesting that Trifarotene reverses some inflammatory processes of the papule. Altogether, these results show that Trifarotene has a unique action in acne treatment by acting on epidermal differentiation and proliferation (Aubert et al., 2018) as well as on innate and adaptive immune cells in acne pathogenesis.
- |||||||||| adapalene / Generic mfg.
[VIRTUAL] CME Improves Dermatologists’ Knowledge and Competence Related to Therapies for Minimizing Acne Scarring () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_157;
Post-CME there was a 22% absolute improvement in knowledge regarding clinical data for trifarotene in truncal acne (69% to 91% pre/post; P <.0001) and in knowledge regarding topical minocycline in moderate to severe acne (64% to 86% pre/post; P <.0001). Dermatologists had a 9% absolute increase in competence regarding the role of adapalene/benzoyl peroxide in scar prevention (79% to 88% pre/post; P <.05).
- |||||||||| Aklief (trifarotene) / Galderma
Clinical, Review, Journal: Trifarotene: A Current Review and Perspectives in Dermatology. (Pubmed Central) - Mar 4, 2021
No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene.
- |||||||||| Aklief (trifarotene) / Galderma
Trial completion date, Trial primary completion date: A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis (clinicaltrials.gov) - Mar 4, 2021
P2, N=120, Recruiting,
Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene. Trial completion date: Dec 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Jul 2021
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Trifarotene for the Treatment of Facial and Truncal Acne. (Pubmed Central) - Feb 13, 2021
Future trials should compare its efficacy and tolerability with that of the older, clinically established retinoids. Despite efficacy, cost may be a prohibitive factor.
- |||||||||| Differin (adapalene) / Galderma
Review, Journal: Selective RAR agonists for acne vulgaris: A narrative review. (Pubmed Central) - Feb 7, 2021
Despite efficacy, cost may be a prohibitive factor. Trifarotene is a new 4th generation retinoid with selective action on RAR-γ receptor alone, which is specific for skin, and it is safe for long-term maintenance therapy with good efficacy and tolerability.
- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea, Differin (adapalene) / Galderma
Journal: Drugs for acne. (Pubmed Central) - Jan 23, 2021
Trifarotene is a new 4th generation retinoid with selective action on RAR-γ receptor alone, which is specific for skin, and it is safe for long-term maintenance therapy with good efficacy and tolerability. No abstract available
- |||||||||| Winlevi (clascoterone cream 1%) / Cassiopea
Review, Journal: New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review. (Pubmed Central) - Jan 8, 2021
Emerging data on the safety and efficacy of spironolactone and isotretinoin challenge current conventions and suggest a need to reconsider drug monitoring guidelines and risk prevention systems. Additional head-to-head data are needed to confirm these novel treatments' utility in treating acne.
- |||||||||| Aklief (trifarotene) / Galderma
Journal: Trifarotene (Aklief) for the Treatment of Acne. (Pubmed Central) - Jan 5, 2021
Additional head-to-head data are needed to confirm these novel treatments' utility in treating acne. No abstract available
- |||||||||| Aklief (trifarotene) / Galderma
Journal: A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream (Pubmed Central) - Dec 17, 2020
These were of lesser degree and tended to develop later at the trunk. Future studies will be required to evaluate the comparative efficacy of trifarotene 50 μg/g cream against other treatments for acne.
- |||||||||| Flagyl (metronidazole) / SLA, metronidazole topical / SLA Pharma
[VIRTUAL] Topical Therapy Pearls () - Nov 26, 2020 - Abstract #FCPANP2020FCPANP_66;
Dr. Kircik ended his talk with the important take away message: vehicles matter.
- |||||||||| Seysara (sarecycline) / Paratek, Almirall, AbbVie, Aklief (trifarotene) / Galderma
[VIRTUAL] New Approaches to Acne Management () - Nov 26, 2020 - Abstract #FCPANP2020FCPANP_43;
The new vehicle for tretinoin lotion and tazarotene foam and lotion decreases irritation, improves adherence and maintains (if not improves) efficacy...Del Rosso also highlighted advancements in topical medications including: a new retinoid, trifarotene, approved for facial and truncal acne; first in class topical anti-androgen, clacoterone, which can be used for men given little systemic absorption; as well as topical minocycline foam...Del Rosso also highlighted advancements in oral regimens including sarecycline, a tetracycline-class antibiotic with more narrow antibiotic activity, a micronized minocycline pellet that allows for immediate and delayed release of the drug all in one tablet, and new formulations of micronized isotretinoin that retains efficacy without having to consume a high-fat/high-calorie meal. Overall, this talk highlighted the amazing advancements in acne therapy and provides a glimpse of the wondrous advancements that are yet to come.
- |||||||||| Aklief (trifarotene) / Galderma
Clinical, Journal: Subject Satisfaction with Trifarotene 50 μg/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series. (Pubmed Central) - Jul 6, 2020
We report a case series of three subjects with moderate facial and truncal acne treated with trifarotene 50 μg/g cream on the face, shoulders, upper back and upper anterior chest for 12 weeks and evaluated by satisfaction questionnaires. This case series illustrating the treatment of facial and truncal acne with trifarotene 50 μg/g cream, in the form of real-world data, describes high overall satisfaction and excellent tolerability to support the use of this new retinoid molecule in the treatment of acne vulgaris on both the face and trunk.
- |||||||||| trifarotene (CD5789) / Galderma
Review, Journal: Trifarotene: First Approval. (Pubmed Central) - Apr 23, 2020
In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.
- |||||||||| trifarotene (CD5789) / Galderma
Journal: Trifarotene (Aklief)-A New Topical Retinoid for Acne. (Pubmed Central) - Apr 9, 2020
This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris. No abstract available
- |||||||||| trifarotene (CD5789) / Galderma
Clinical, Journal: Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid. (Pubmed Central) - Feb 6, 2020
Results showed that trifarotene 50 µg/g cream is well tolerated and safe, even when applied under maximized conditions in adults and pediatric acne patients presenting with severe acne. Daily use of trifarotene 50 µg/g cream was not associated with cardiovascular effects and did not result in drug-drug interaction in women of childbearing potential using oral contraception.
- |||||||||| Aklief (trifarotene) / Galderma
Enrollment open, Trial completion date, Trial primary completion date: A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis (clinicaltrials.gov) - Feb 5, 2020
P2, N=120, Recruiting,
Daily use of trifarotene 50 µg/g cream was not associated with cardiovascular effects and did not result in drug-drug interaction in women of childbearing potential using oral contraception. Not yet recruiting --> Recruiting | Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Feb 2020 --> Sep 2020
- |||||||||| trifarotene (CD5789) / Galderma Laboratories
Journal: Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. (Pubmed Central) - Nov 28, 2019
Not yet recruiting --> Recruiting | Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Feb 2020 --> Sep 2020 Based on its RARγ selectivity, rapid degradation in human hepatic microsomes and pharmacological properties including potent modulation of epidermal processes, topical treatment with trifarotene could result in good efficacy and may present a favourable safety profile in acne and ichthyotic disorders.
- |||||||||| trifarotene (CD5789) / Galderma Laboratories
Clinical, P3 data, Journal: Randomized Phase 3 Evaluation of Trifarotene 50 μG/G Cream Treatment Of Moderate Facial And Truncal ACNE. (Pubmed Central) - Oct 29, 2019
Based on its RARγ selectivity, rapid degradation in human hepatic microsomes and pharmacological properties including potent modulation of epidermal processes, topical treatment with trifarotene could result in good efficacy and may present a favourable safety profile in acne and ichthyotic disorders. These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in treatment of both facial and truncal acne.
|
